Loading clinical trials...

RECRUITINGPHASE2

A Phase 2 Study of HB0017 in Psoriasis Patients

A Multicenter, Randomized, Double-blind Phase 2 Clinical Study Evaluating the Efficacy and Safety of Different Administration Regimens of HB0017 Injection in Patients With Moderate to Severe Plaque Psoriasis

NCT06592274•Huabo Biopharm Co., Ltd.

View on ClinicalTrials.gov

Summary

This study is a randomized, double-blind phase 2 clinical trial aimed at exploring the efficacy, safety, and immunogenicity of HB0017 injection with different dosing regimens in the treatment of moderate to severe plaque psoriasis in subjects

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Male or female subjects aged 18-75 years (inclusive)
•Chronic plaque psoriasis (PSO) for at least 6 months prior to the randomization.
•Psoriasis Area Severity Index (PASI) \&gt;=12 and body surface area (BSA) affected by PSO \&gt;=10% and Static Physician Global Assessment (sPGA) score \&gt;=3.
•Subjects who are suitable for systemic treatment or phototherapy for psoriasis as judged by the investigator
•Subjects who are able to use effective contraception from the screening period to 6 months after the last dose

Exclusion Criteria

•Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic and/or guttate psoriasis) at screening or baseline Drug-induced psoriasis
•Ongoing use of prohibited treatments
•Any active infection (other than common cold) within 14 days
•Serious infection defined as requiring hospitalization or iv anti-infective(s) within 1 month prior to randomization
•Have previously received any drug that directly targets IL-17 or IL-17 receptor
•Have concurrent or recent use of any biologic agent within the following washout periods: etanercept \<28 days; infliximab and adalimumab \<60 days; golimumab \< 90 days; anti-IL-12/anti-IL-23 or anti-IL-23p19 antibody drugs \<6 months; or other anti-psoriatic therapy not listed herein within its 5 half-lives prior to randomization
•A history of inflammatory bowel disease or other serious autoimmune disease
•Previously diagnosed with serious mental illness such as anxiety, depression or suicidal tendency

Locations (18)

The First Affiliated Hospital of Bengbu Medical College

Bengbu, Anhui, China

Southern Medical University Dermatology Hospital

Guangzhou, Guangdong, China

Xiangya Hospital of Central South University

Changsha, Hunan, China

Wuxi Second People's Hospital

Wuxi, Jiangsu, China

Jiangsu University Affiliated Hospital

Zhenjiang, Jiangsu, China

Jilin University Second Hospital

Changchun, Jilin, China

Shandong First Medical University Affiliated Dermatology Hospital

Jinan, Shandong, China

Jining First People's Hospital

Jining, Shandong, China

Xingtai People's Hospital

Xingtai, Shandong, China

Shanxi Medical University Second Hospital

Taiyuan, Shanxi, China

Key Dates

Start Date

September 30, 2024

Primary Completion Date

April 30, 2025

Completion Date

January 30, 2026

Last Updated

September 15, 2025

Enrollment

200

ESTIMATED participants

Conditions

Psoriasis (PsO)

Interventions

HB0017

BIOLOGICAL

HB0017

BIOLOGICAL

HB0017

BIOLOGICAL

Microbiome and Clinical Response to Probiotics and Methotrexate in Early Psoriasis: a Pilot Study

NCT07169019

Psoriasis (PsO)

View study

ACTIVE_NOT_RECRUITING

Evaluation of TNF-α, IL-17A, and YKL-40 in GCF and Serum of Psoriasis Patients and Healthy Controls

NCT06897722

Psoriasis (PsO)Periodontal Disease

View study

NOT_YET_RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 15, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Phase 2 Study of HB0017 in Psoriasis Patients

Inclusion Criteria

Exclusion Criteria

Microbiome and Clinical Response to Probiotics and Methotrexate in Early Psoriasis: a Pilot Study

Evaluation of TNF-α, IL-17A, and YKL-40 in GCF and Serum of Psoriasis Patients and Healthy Controls

Research on the Extraction of Tongue and Facial Diagnosis Features of Psoriasis Vulgaris in Traditional Chinese Medicine and Its Correlation With Laboratory Indicators